针对KRAS突变非小细胞肺癌的第一线治疗方法:现状和未来前景
Qi He1, Xiaoyan Liu1, Liyan Jiang2
1Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
针对KRAS突变非小细胞肺癌 (NSCLC) 的第一线治疗包括免疫疗法和化疗. 新兴的KRAS抑制剂与免疫疗法相结合,未来有望改善NSCLC治疗的结果.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 药理学 药理学是指药理学的学科.
背景情况:
- KRAS突变在非小细胞肺癌 (NSCLC) 中普遍存在,影响患者的预后.
- 针对NSCLC中的KRAS历来存在重大挑战.
- 目前对KRAS突变NSCLC的第一线治疗包括免疫治疗,化疗和化疗免疫治疗.
研究的目的:
- 审查和总结KRAS突变NSCLC的第一线治疗现有证据.
- 为了比较不同一线治疗方案的治疗结果和相关生物标志物.
- 讨论新兴的治疗方法,包括KRAS抑制剂及其潜在的组合疗法.
主要方法:
- 关于KRAS突变NSCLC的第一线治疗方法的当前证据的综合文献综述.
- 对各种治疗方案的治疗结果和生物标志物的比较分析.
- 讨论新药和组合策略,特别是KRAS抑制剂与免疫治疗.
主要成果:
- 免疫疗法,化疗和化疗免疫疗法已成为KRAS突变NSCLC的第一线治疗方案.
- 总结了对这些疗法结果和生物标志物的比较证据.
- 克拉斯抑制剂是未来治疗开发的一个有希望的领域,特别是与免疫疗法结合使用.
结论:
- 本综述提供了当前对KRAS突变NSCLC的第一线治疗选择的见解.
- 涉及KRAS抑制剂和免疫治疗的组合疗法可能提供一个有前途的未来方向.
- 对新型药物的进一步研究对于推进KRAS突变NSCLC的治疗前景至关重要.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation
The Ras Gene
Ras is a...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
